Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thioridazine for schizophrenia.

A Sultana1, J Reilly, M Fenton

  • 1St Andrews Hospital, Addenbrooks NHS Trust, Billing Road, Northampton, Northamptonshire, UK, NN1 5DG. asultana@doctors.org.uk

The Cochrane Database of Systematic Reviews
|July 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pattern of Respiratory Tract Infections in Nephrotic Syndrome Presented with Relapse.

Mymensingh medical journal : MMJ·2025
Same author

Production and purification of molecular <sup>225</sup>Ac at CERN-ISOLDE.

Journal of radioanalytical and nuclear chemistry·2025
Same author

Early Postoperative Outcome Following Laparoscopic Surgeries in Rectal Malignancies.

Mymensingh medical journal : MMJ·2024
Same author

Epidemiology of healthcare-associated Pseudomonas aeruginosa in intensive care units: are sink drains to blame?

The Journal of hospital infection·2024
Same author

Gallbladder Rupture Following Blunt Trauma.

Irish medical journal·2024
Same author

Synchronous Tumour: A Rare Case Report.

Mymensingh medical journal : MMJ·2023
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Thioridazine is an effective antipsychotic for schizophrenia, comparable to other neuroleptics. It shows similar efficacy and adverse events, with potentially fewer extrapyramidal side effects, especially in the short term.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Thioridazine, a phenothiazine, is used for schizophrenia, particularly in the elderly, due to perceived lower extrapyramidal side effects.
  • Potential cognitive adverse events and rare pigmentary retinopathy are noted.
  • This review examines its efficacy and safety in schizophrenia treatment.

Purpose of the Study:

  • To evaluate the effects of thioridazine in schizophrenia patients.
  • To specifically assess its impact on elderly individuals with schizophrenia.

Main Methods:

  • Conducted comprehensive electronic database searches (1966-1999) and contacted pharmaceutical companies.
  • Included all randomized clinical trials comparing thioridazine to other treatments for psychosis.

Related Experiment Videos

  • Employed rigorous data extraction and analysis, calculating Relative Risks and Weighted Mean Differences, with a 40% loss to follow-up exclusion criterion.

    • Main Results:

    • Thioridazine showed similar efficacy to placebo in short-term global state changes but favored it at six months, with reduced early withdrawal.
    • Compared to typical antipsychotics, thioridazine demonstrated comparable efficacy and similar adverse event profiles, including anticholinergic and sedative effects.
    • Parkinsonism was less frequent with thioridazine in the short term, with no significant differences noted against clozapine in one small study.

    Conclusions:

    • Thioridazine is an antipsychotic with efficacy similar to commonly used neuroleptics for schizophrenia.
    • Its adverse event profile is comparable to other drugs, potentially offering a lower incidence of extrapyramidal symptoms.
    • Despite data gaps, thioridazine is a viable treatment option for schizophrenia.